Literature DB >> 18462969

Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report.

Zvi Laron1, Shira Ginsberg, Muriel Webb.   

Abstract

BACKGROUND: There is little information on the relationship between growth hormone/insulin-like growth factor-I (GH/IGF-I) deficiency or IGF-I treatment on nonalcoholic fatty liver disease (NAFLD) a disorder linked to obesity and insulin resistance.
OBJECTIVE: To find out whether the markedly obese patients with Laron syndrome (LS) and GH gene deletion have fatty livers.
SUBJECTS: We studied 11 untreated adult patients with LS (5M, 6F), five girls with LS treated by IGF-I and five adult patients with GH gene deletion (3M, 3F), four previously treated by hGH in childhood.
METHODS: Fatty liver was quantitatively evaluated by ultrasonography using a phase array US system (HITACHI 6500, Japan). Body adiposity was determined by DEXA, and insulin resistance was estimated by HOMA-IR using the fasting serum glucose and insulin values.
RESULTS: Six out of 11 adult patients with LS, two out of the five IGF-I treated girls with LS and three out of five adult hGH gene deletion patients were found to have NAFLD (nonalcoholic fatty liver disease).
CONCLUSION: NAFLD is a frequent complication in untreated and treated congenital IGF-I deficiency. No correlation between NAFLD and age, sex, degree of obesity, blood lipids, or degree of insulin resistance was observed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18462969     DOI: 10.1016/j.ghir.2008.03.003

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  17 in total

1.  Prenatal dexamethasone exposure potentiates diet-induced hepatosteatosis and decreases plasma IGF-I in a sex-specific fashion.

Authors:  David L Carbone; Damian G Zuloaga; Ryoko Hiroi; Chad D Foradori; Marie E Legare; Robert J Handa
Journal:  Endocrinology       Date:  2011-11-08       Impact factor: 4.736

2.  Two-year body composition analyses of long-lived GHR null mice.

Authors:  Darlene E Berryman; Edward O List; Amanda J Palmer; Min-Yu Chung; Jacob Wright-Piekarski; Ellen Lubbers; Patrick O'Connor; Shigeru Okada; John J Kopchick
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-11-09       Impact factor: 6.053

Review 3.  Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR-/-) mouse.

Authors:  Edward O List; Lucila Sackmann-Sala; Darlene E Berryman; Kevin Funk; Bruce Kelder; Elahu S Gosney; Shigeru Okada; Juan Ding; Diana Cruz-Topete; John J Kopchick
Journal:  Endocr Rev       Date:  2010-12-01       Impact factor: 19.871

4.  GH Knockout Mice Have Increased Subcutaneous Adipose Tissue With Decreased Fibrosis and Enhanced Insulin Sensitivity.

Authors:  Edward O List; Darlene E Berryman; Mathew Buchman; Elizabeth A Jensen; Kevin Funk; Silvana Duran-Ortiz; Yanrong Qian; Jonathan A Young; Julie Slyby; Savannah McKenna; John J Kopchick
Journal:  Endocrinology       Date:  2019-07-01       Impact factor: 4.736

5.  Context-Specific Growth Hormone Signaling through the Transcription Factor STAT5: Implications for the Etiology of Hepatosteatosis and Hepatocellular Carcinoma.

Authors:  Kyung Hyun Yoo; Myunggi Baik; Lothar Hennighausen
Journal:  Genes Cancer       Date:  2011-01

Review 6.  The growth hormone receptor: mechanism of activation and clinical implications.

Authors:  Andrew J Brooks; Michael J Waters
Journal:  Nat Rev Endocrinol       Date:  2010-07-27       Impact factor: 43.330

Review 7.  Somatotropic signaling: trade-offs between growth, reproductive development, and longevity.

Authors:  Andrzej Bartke; Liou Y Sun; Valter Longo
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

8.  The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors.

Authors:  Fernando Cordido; Jesús Garcia-Buela; Susana Sangiao-Alvarellos; Teresa Martinez; Ovidio Vidal
Journal:  Mediators Inflamm       Date:  2010-01-21       Impact factor: 4.711

9.  Growth Hormone Inhibits Hepatic De Novo Lipogenesis in Adult Mice.

Authors:  Jose Cordoba-Chacon; Neena Majumdar; Edward O List; Alberto Diaz-Ruiz; Stuart J Frank; Anna Manzano; Ramon Bartrons; Michelle Puchowicz; John J Kopchick; Rhonda D Kineman
Journal:  Diabetes       Date:  2015-05-26       Impact factor: 9.461

Review 10.  Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development.

Authors:  Kristina M Mueller; Madeleine Themanns; Katrin Friedbichler; Jan-Wilhelm Kornfeld; Harald Esterbauer; Jan P Tuckermann; Richard Moriggl
Journal:  Mol Cell Endocrinol       Date:  2012-04-30       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.